ArticlemAbs
Improving biophysical properties of a bispecific antibody scaffold to aid developability: quality by molecular design.
Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed.
- Review
- Targeted extracellular degradation of LRP8 promotes ferroptosis in cancer cells.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Folding-mediated secretion of pure bispecific antibodies.Nature biotechnology · 2026Article
- IMGT-NC Engineered Variants of INN Therapeutic IG or Antibodies and Related IgSF Proteins (TR, FPIA and CPCA): Bridging Sequences, Structures and Functions for AI.Biomolecules · 2026Review
- Engineering Fc heterodimerization via asymmetric β-strand reconfiguration for bispecific antibody assembly.Journal of biological engineering · 2026Article
- Challenges and solutions for upstream processing of complex biologics.Antibody therapeutics · 2026Review
- Review
- Hijacking Extracellular Targeted Protein Degrader-Drug Conjugates for Enhanced Drug Delivery.Journal of the American Chemical Society · 2025Article
- Immunoglobulin divalence promotes B-cell antigen receptor cluster scale-dependent functions.Cellular & molecular immunology · 2025Article
- A long-lasting prolactin stimulates galactopoiesis in mice.iScience · 2025Article
- Low-density lipoprotein receptor-targeting chimeras for membrane protein degradation and enhanced drug delivery.bioRxiv : the preprint server for biology · 2025Article
- JNJ-78306358, a first-in-class bispecific T cell engaging antibody targeting CD3 and HLA-G.iScience · 2025Article
- Engineered protein G variants for multifunctional antibody-based assemblies.Protein science : a publication of the Protein Society · 2025Article
- Assessing the Manufacturability and Critical Quality Attribute Profiles of Anti-IL-8 Immunoglobulin G Mutant Variants.Molecular pharmaceutics · 2024Article
- End-To-End Automated Intact Protein Mass Spectrometry for High-Throughput Screening and Characterization of Bispecific and Multispecific Antibodies.Analytical chemistry · 2024Article
- Bispecific antibody drug conjugates: Making 1+1>2.Acta pharmaceutica Sinica. B · 2024Review
- Combinatorially restricted computational design of protein-protein interfaces to produce IgG heterodimers.Science advances · 2024Article
- A novel T cell-redirecting anti-GPRC5D × CD3 bispecific antibody with potent antitumor activity in multiple myeloma preclinical models.Scientific reports · 2024Article
- Next generation of multispecific antibody engineering.Antibody therapeutics · 2024Review
- Design and engineering of bispecific antibodies: insights and practical considerations.Frontiers in bioengineering and biotechnology · 2024Review
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While the concept of Quality-by-Design is addressed at the upstream and downstream process development stages, we questioned whether there are advantages to addressing the issues of biologics quality early in the design of the molecule based on fundamental biophysical characterization, and thereby reduce complexities in the product development stages. Although limited number of bispecific therapeutics are in clinic, these developments have been plagued with difficulty in producing materials of sufficient quality and quantity for both preclinical and clinical studies. The engineered heterodimeric Fc is an industry-wide favorite scaffold for the design of bispecific protein therapeutics because of its structural, and potentially pharmacokinetic, similarity to the natural antibody. Development of molecules based on this concept, however, is challenged by the presence of potential homodimer contamination and stability loss relative to the natural Fc. We engineered a heterodimeric Fc with high heterodimeric specificity that also retains natural Fc-like biophysical properties, and demonstrate here that use of engineered Fc domains that mirror the natural system translates into an efficient and robust upstream stable cell line selection process as a first step toward a more developable therapeutic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.